Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

G Mountzios,E Samantas, K Senghas,E Zervas,J Krisam,K Samitas,F Bozorgmehr, J Kuon,S Agelaki,S Baka,I Athanasiadis, L Gaissmaier, M Elshiaty, L Daniello,A Christopoulou,G Pentheroudakis,E Lianos,H Linardou, K Kriegsmann,P Kosmidis,R El Shafie,M Kriegsmann,A Psyrri, C Andreadis, E Fountzilas,C-P Heussel,F J Herth,H Winter, C Emmanouilides, G Oikonomopoulos,M Meister,T Muley,H Bischoff,Z Saridaki,E Razis, E-I Perdikouri,A Stenzinger, I Boukovinas, M Reck,K Syrigos,M Thomas,P Christopoulos

ESMO Open（2021）

引用 33|浏览39

暂无评分

摘要

•ALI is prognostic and predictive for patients with advanced NSCLC treated with immunotherapy monotherapy, but not chemo-immunotherapy.•Its association with outcomes is stronger than that of other parameters (PD-L1 TPS, NLR, lung immune prognostic index, EPSILoN).•For PD-L1-high patients, an ALI score >18 could assist the selection of cases that do not need addition of chemotherapy.

查看译文

关键词

advanced lung cancer inflammation index,immunotherapy,non-small-cell lung cancer,PD-L1,neutrophil-to-lymphocyte ratio

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要